LENZ Therapeutics, Inc. commercializes VIZZ (aceclidine ophthalmic solution) 1.44%, an FDA-approved aceclidine-based prescription eye drop for the treatment of presbyopia in adults. Company news centers on U.S. commercialization, product availability, financial results, prescribing and product-revenue updates, and consumer and professional education for the ophthalmic product.
Recurring LENZ developments also include regulatory submissions for VIZZ outside the United States, international licensing and commercialization partnerships, investor-conference participation, and safety or pharmacovigilance communications related to real-world product use. VIZZ is described by the company as a once-daily, preservative-free, single-dose vial product that uses a predominantly pupil-selective miotic mechanism to improve near vision.
LENZ Therapeutics reported positive topline data from Phase 3 CLARITY study for presbyopia, selected LNZ100 as lead candidate, and anticipates New Drug Application submission in mid-2024. The company completed a merger with Graphite Bio, raised $53.5 million in a private placement, and has a strong cash position of $213.3 million. LENZ aims to provide a compelling treatment option for presbyopia patients and create significant value for shareholders.
LENZ Therapeutics, Inc. will announce its first quarter 2024 financial results and business update on May 8, 2024. The company focuses on developing aceclidine-based eye drops for presbyopia. A webcast will be held to discuss the results and updates.
Summary not available.
Summary not available.
Summary not available.